30 closest matches · ranked by relevance
Acute Liver Failure · Acute Liver Injury
Primary: Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability — 0; 0…
Liver Failure, Acute on Chronic
Primary: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate — 74; 124; 74 Participants
Acute Liver Failure · Hepatic Encephalopathy
Primary: Survival — 68; 76 Participants — p=0.19
Acute Alcoholic Hepatitis
Primary: Overall Survival — 57; 66 Participants — p=0.904
Acute Liver Failure
Primary: Peak Percent Dose Recovery (PDR) Value — 10.2; 1.9 percentage per hour
Biliary Atresia
Primary: Number of Patients With Biliary Atresia (BA) Achieving Total Serum Bile Acids Less Than or Equal to 10 *U*Mol/L Within 24 Weeks of Kasai Portoenterostomy (KP) — 0…
Drug Toxicity · Healthy
Primary: The Proportion of Subjects Treated With Long-term Acetaminophen (4 g/Day) That Develops Persistent ALT Elevations. — 204; 47; 1; 0 participants
Liver Cirrhosis
Primary: Patient Survival — 5; 6; 4; 10 participants — p=0.4340
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis
Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change
Liver Cirrhosis
Primary: Number of Participants With Serious Adverse Events Related to Injection — 0 Participants
Liver Disease
Primary: Number of Patients Who Tolerated the Maximum Dose — 5 Participants
Hepatorenal Syndrome
Primary: Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline…
Urea Cycle Disorder
Primary: Liver Stiffness as Measured by Shear Wave Elastography — 13; 14 Participants
Alcoholic Liver Disease
Primary: Liver Enzymes(ALT) — 66; 48 IU/L
Alcoholic Hepatitis
Primary: The Number of Subjects With Unexpected Serious Adverse Events. — 0; 0; 0 Participants
Parenteral Nutrition-related Hepatitis
Primary: Disease Progression as Measured by Serum Levels of Hepatic Enzymes
Liver Transplant; Complications · NAFLD
Primary: Number of Participants With Adverse Events Assessed by CTCAE — 12 Participants
Liver Transplant
Primary: Participants With Early Liver Allograft Dysfunction (EAD) — 19 Participants
Paracetamol Overdose
Primary: Safety Events — 6; 6; 6; 6 participants
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Severe Sepsis
Primary: F2-isoprostanes After 72 Hours of Acetaminophen or Placebo — 33.4; 40.15 pg/mL — p=0.353
Cholestasis · Cholestasis of Parenteral Nutrition
Primary: Time to Resolution of Parenteral Nutrition Associated Cholestasis Prior to End of Study — 38.02 Days
Acute Renal Failure
Primary: 60-day All-cause Mortality — 302; 289 participants — p=0.47
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Chronic Liver Disease
Primary: Agreement in Measured Liver Stiffness Between ARFI and MRE — 3.21; 2.48; 1.81; 2.0 kPa
NAFLD
Primary: Number of Subjects With Incidence of Study Product Emergent Adverse Events (AEs) and Any Serious Adverse Events (SAEs) — 10; 8; 13; 2 participants
Decompensated Cirrhosis and Ascites
Primary: Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event — 33.5; 38.6 percentage of participants — p=0.17
Mild Hepatic Injury
Primary: Changes in ALT(Alanine Transaminase) — 61.08; 55.68; 44.92; 53.82 IU/L
Hepatic Impairment · Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Soticlestat — 3230; 3666; 1435; 1705 nanogram per milliliter (ng/mL)
Thrombotic Microangiopathies · Hematologic Diseases
Primary: The Incidence of TA-TMA. — 5; 15 Participants